Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
Company profile
Ticker
NEOS
Exchange
Website
CEO
Gerald McLaughlin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Neos Therapeutics, LP • Neos Therapeutics Brands, LLC • Neos Therapeutics Commercial, LLC • PharmaFab Texas, LLC ...
NEOS stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
30 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
EFFECT
Notice of effectiveness
26 Mar 21
8-K
Aytu BioScience Announces Close of Merger with Neos Therapeutics
22 Mar 21
425
Business combination disclosure
22 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 21
Transcripts
NEOS
Earnings call transcript
2020 Q3
9 Nov 20
NEOS
Earnings call transcript
2020 Q2
10 Aug 20
NEOS
Earnings call transcript
2020 Q1
11 May 20
NEOS
Earnings call transcript
2019 Q4
13 Mar 20
NEOS
Earnings call transcript
2019 Q3
8 Nov 19
NEOS
Earnings call transcript
2019 Q2
8 Aug 19
NEOS
Earnings call transcript
2019 Q1
9 May 19
NEOS
Earnings call transcript
2018 Q4
14 Mar 19
NEOS
Earnings call transcript
2018 Q3
9 Nov 18
NEOS
Earnings call transcript
2018 Q2
8 Aug 18
Latest ownership filings
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.74 mm | 12.74 mm | 12.74 mm | 12.74 mm | 12.74 mm | 12.74 mm |
Cash burn (monthly) | (no burn) | 1.08 mm | 1.64 mm | 1.31 mm | 704.67 k | 983.58 k |
Cash used (since last report) | n/a | 46.46 mm | 70.10 mm | 56.13 mm | 30.19 mm | 42.14 mm |
Cash remaining | n/a | -33.71 mm | -57.35 mm | -43.39 mm | -17.44 mm | -29.39 mm |
Runway (months of cash) | n/a | -31.1 | -35.1 | -33.1 | -24.8 | -29.9 |
Institutional ownership, Q3 2021
0.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 216.00 k |
Total shares | 337.26 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Goldman Sachs & Co | 337.25 k | $211.00 k |
BNP Paribas Arbitrage | 10.00 | $5.00 k |